Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 51 (8), 373-377

BLT2, a Leukotriene B4 Receptor 2, as a Novel Prognostic Biomarker of Triple-Negative Breast Cancer


BLT2, a Leukotriene B4 Receptor 2, as a Novel Prognostic Biomarker of Triple-Negative Breast Cancer

JaeIn Park et al. BMB Rep.


Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. [BMB Reports 2018; 51(8): 373-377].

Conflict of interest statement


The authors have no conflicting interests.


Fig. 1
Fig. 1
Comprehensive overview of the BLT2 signaling pathways. See text for details.
Fig. 2
Fig. 2
The Kaplan-Meier curves of the overall survival rates of patients with lymph node metastasis stratified by BLT2 expression (n = 545; HR = 1.341; 95% CI = (1.036, 1.735), P = 0.03).
Fig. 3
Fig. 3
Overall survival of breast cancer patients with and without up-regulated BLT2 expression at the mRNA level and a pie chart of the patients’ HER2 status. Absolute patient numbers for each subgroup are indicated.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles


    1. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702–4710. doi: 10.1158/1078-0432.CCR-10-0939. - DOI - PMC - PubMed
    1. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–692. doi: 10.1038/nrclinonc.2010.154. - DOI - PubMed
    1. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29–33. doi: 10.3816/CBC.2009.n.005. - DOI - PubMed
    1. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307–313. doi: 10.1007/s10555-006-9000-8. - DOI - PubMed
    1. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003;69:123–134. doi: 10.1016/S0952-3278(03)00073-5. - DOI - PubMed

MeSH terms